San Diego‑based Iambic is advancing a physics‑informed, automation‑driven platform aimed at compressing the small‑molecule discovery timeline to roughly two years from chemistry to clinic. The company combines AI algorithms with automated chemistry and has begun moving small molecules into clinical studies while attracting partnership interest. Iambic’s approach reflects growing investor and industry appetite for integrated AI‑automation stacks that promise faster lead optimization and candidate selection.